Live: One Dial-in One Attendee
Corporate Live: Any number of participants
Recorded: Access recorded version, only for one participant unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)
Corporate Recorded: Access recorded version, Any number of participants unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)
Verification and validation requirements have always been part of the US FDA’s GMPs. Yet companies still struggle with the performance of and documentation of Equipment, Process, Software, and quality management system validations.
Starting with a Master Validation Plan, evaluating its elements against ISO 14971 hazard analysis/risk management allows the development of meaningful product validations. The roles of different V&V protocols.
How to employ equipment/process DQs, IQs, OQs, and PQs, or their equivalents per ASTM E2500, against a background of limited company resources (personnel, budget, time). A matrix simplifies “as-product”, “in-product”, process, and equipment, et al, software V&VT, assuring key FDA requirements are not overlooked. The mandatory, but frequently neglected, 11 documents that must be included in a software V&V. The QMS and 21 CFR Part 11 must be considered.
Why should you Attend: FDA Warning Letters and recent high-profile recalls indicate major cGMP deficiencies in many companies. One major failing is the lack of sufficient or targeted risk-based company-wide V&V planning. However, with increasing technology, both industry and regulatory agencies' expectations have increased. Recent high-profile field problems indicate that V&V activities are not planned or carried out as completely as expected, and may not be fully utilizing the power of current risk management tools, as identified in ISO 14971.
The FDA / ICH Q-series provide valuable insights for all regulated industries, not just pharma. The billions of dollars spent by the industry annually for V&V are not providing the product safety or efficacy seemingly promised. For most companies, the fixes are not rocket science, but proper up-front V&V planning and execution.
Areas Covered in the Session:
Subscribe for Compliance Alerts Research Reports Absolutely Free